JCR Pharmaceuticals Co., Ltd.

As of March 31, 2026, JCR Pharmaceuticals Co., Ltd. carries a market capitalization of 69.29B, placing it among publicly traded companies globally. Its enterprise value stands at 109.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

JCR Pharmaceuticals Co., Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of March 31, 2026, JCR Pharmaceuticals Co., Ltd. has 121.99M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, JCR Pharmaceuticals Co., Ltd. maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, JCR Pharmaceuticals Co., Ltd.'s stock has declined approximately 14.42% over the past 52 weeks. The 50-day moving average sits at 518.60, while the 200-day moving average is 557.55.

As of March 31, 2026, JCR Pharmaceuticals Co., Ltd. holds 14.01B in cash and equivalents against 53.89B in total debt, resulting in a net debt position of 39.89B. Total book value stands at 46.94B, with working capital of 7.94B providing operational flexibility.

JCR Pharmaceuticals Co., Ltd.'s most recent stock split took place on September 29, 2020 with a 1:4 split ratio.